Canadian Plasma Clinics Pause Donations After Donor Deaths 2026

Canadian plasma clinics have paused collections after the deaths of two donors, raising urgent safety concerns. The private plasma donation chain, operated by Spanish healthcare company Grifols, temporarily halted operations at its 17 clinics across Canada following a government investigation into potential unsafe practices. This decision comes after Health Canada issued a formal notice of non-compliance for failure to follow blood regulations, marking a critical moment for the country's plasma donation industry.

What Led to the Pause in Plasma Collections?

The pause was triggered by the deaths of two donors in Manitoba, occurring in October 2025 and January 2026. Both donors experienced distress during the donation process, with one victim identified as Rodiyat Alabede, a 22-year-old international student who died of cardiac arrest shortly after donating plasma in Winnipeg. Health Canada initially reported no link between her death and the donation, but patient advocates have called for a new inquest after uncovering significant medical discrepancies between the autopsy and the official medical summary.

Grifols, the only private plasma clinic operator in Canada, informed Health Canada of its decision to pause collections on the same day the agency issued a formal notice of non-compliance. This action underscores the seriousness of the regulatory violations and the potential risks to donors. The company's voluntary pause is a proactive step, but it raises questions about the safety protocols in place at private plasma collection facilities.

Health Canada's Investigation and Findings

Health Canada's inspection reports from May revealed deficiencies in the clinics' operations. According to patient advocates, staff were extracting plasma from donors without proper training or safety knowledge. Kat Lanteigne, a safe blood campaigner representing Alabede's family, stated, "They had staff taking plasma from donors who did not know how to extract plasma in a safe manner." The failures were described as egregious, leading to more questions than answers about the safety of private plasma donation in Canada.

The investigation is ongoing, and Health Canada has not yet released a full public report. However, the notice of non-compliance indicates that Grifols failed to adhere to blood regulations, which are designed to protect donor health and ensure the safety of the plasma supply. This incident highlights the need for stricter oversight and transparency in the industry.

Comparing Private vs. Public Plasma Donation

To understand the implications, it's helpful to compare private and public plasma donation systems. The table below outlines key differences:

This comparison shows that while private clinics offer convenience and compensation, they may compromise on safety standards. The deaths in Manitoba highlight the potential consequences of inadequate regulation and training.

Key Takeaways for Donors and the Public

• Plasma donation safety is paramount; always verify the clinic's compliance with Health Canada regulations.
• Be aware of the signs of distress during donation, such as dizziness, chest pain, or shortness of breath, and report them immediately.
• Advocate for transparent reporting and independent investigations when incidents occur.
• Consider donating through public blood services, which have stricter oversight and no profit motive.
• Stay informed about Health Canada's notices and inspection reports for any plasma clinic.

What Happens Next for Grifols and Canadian Plasma Donation?

The pause in collections is a significant setback for Grifols, which has been expanding its presence in Canada. The company must now address the regulatory violations and implement corrective actions to regain trust. Health Canada's investigation will likely lead to stricter enforcement and possibly new regulations for private plasma clinics. For donors, this incident serves as a reminder to prioritize safety and ask questions about the procedures in place.

In the meantime, patients who rely on plasma-derived therapies may face shortages, as the country's supply is impacted. Canadian Blood Services and other public entities may need to step up to meet demand. The long-term implications for the private plasma industry in Canada are uncertain, but this tragedy could reshape the regulatory landscape and how plasma donation is managed.

FAQ

In conclusion, the pause in Canadian plasma collections after donor deaths is a wake-up call for the industry. It underscores the need for rigorous safety protocols, transparent oversight, and a donor-first approach. As investigations continue, the priority must be to prevent such tragedies and ensure that plasma donation remains a safe and life-saving act.